119 related articles for article (PubMed ID: 23117856)
21. In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance.
Wang W; Yin L; Gonzalez-Malerva L; Wang S; Yu X; Eaton S; Zhang S; Chen HY; LaBaer J; Tao N
Sci Rep; 2014 Oct; 4():6609. PubMed ID: 25312029
[TBL] [Abstract][Full Text] [Related]
22.
Li F; Wu Y; Shi Y; Liu X; Xie Y; Liu S
Acta Biochim Biophys Sin (Shanghai); 2024 Mar; 56(3):462-473. PubMed ID: 38379418
[TBL] [Abstract][Full Text] [Related]
23. A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer.
Zhao L; Chang F; Tong Y; Yin J; Xu J; Li H; Du L; Jiang Y
Adv Sci (Weinh); 2024 Apr; 11(16):e2308316. PubMed ID: 38380506
[TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of a potent and selective HUNK inhibitor for treatment of HER2+ breast cancer.
Dilday T; Abt M; Ramos-Solís N; Dayal N; Larocque E; Oblak AL; Sintim HO; Yeh ES
Cell Chem Biol; 2024 May; 31(5):989-999.e7. PubMed ID: 38307028
[TBL] [Abstract][Full Text] [Related]
25. Anti-HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone-Fused Enediyne.
Feng X; Wen Z; Zhu X; Yan X; Duan Y; Huang Y
Adv Sci (Weinh); 2024 May; 11(17):e2307865. PubMed ID: 38355309
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer.
Velázquez-Vega LE; Rivera-Robles M; Sánchez-Álvarez AO; Vivas-Mejía PE; Aponte-Reyes M; Cruz-Collazo AM; Grafals-Ruiz N; Dorta-Estremera S; Hernández-O'Farrill E; Vlaar CP; Dharmawardhane S
Transl Oncol; 2024 Jun; 44():101928. PubMed ID: 38489873
[TBL] [Abstract][Full Text] [Related]
27. Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions.
Sekar AP; Nurmala S; Matsuura E; Tan XW; Rahmasari R; Sauriasari R
Breast Cancer (Auckl); 2024; 18():11782234241240173. PubMed ID: 38779416
[TBL] [Abstract][Full Text] [Related]
28. Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity.
Nishie M; Suzuki E; Hattori M; Kawaguch K; Kataoka TR; Hirata M; Pu F; Kotake T; Tsuda M; Yamaguchi A; Sugie T; Toi M
Cancer Immunol Immunother; 2021 Mar; 70(3):817-830. PubMed ID: 33000417
[TBL] [Abstract][Full Text] [Related]
29. Cancer cells grown in 3D under fluid flow exhibit an aggressive phenotype and reduced responsiveness to the anti-cancer treatment doxorubicin.
Azimi T; Loizidou M; Dwek MV
Sci Rep; 2020 Jul; 10(1):12020. PubMed ID: 32694700
[TBL] [Abstract][Full Text] [Related]
30. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.
Khankin EV; Mutter WP; Tamez H; Yuan HT; Karumanchi SA; Thadhani R
PLoS One; 2010 Feb; 5(2):e9246. PubMed ID: 20169072
[TBL] [Abstract][Full Text] [Related]
31. Exploring Anticancer Properties of Medicinal Plants against Breast Cancer by Downregulating Human Epidermal Growth Factor Receptor 2.
Gupta S; Prem R; Sethy C; Shrivastava S; Singh M; Yadav P; Huddar VG; Prajapati PK; Roy A; Sundd M; Patel AK
J Agric Food Chem; 2024 May; 72(17):9717-9734. PubMed ID: 38624258
[TBL] [Abstract][Full Text] [Related]
32. Erythropoietin increases macrophage-mediated T cell suppression.
Wood MA; Goldman N; DePierri K; Somerville J; Riggs JE
Cell Immunol; 2016; 306-307():17-24. PubMed ID: 27262376
[TBL] [Abstract][Full Text] [Related]
33. Strategic Trastuzumab Mediated Crosslinking Driving Concomitant HER2 and HER3 Endocytosis and Degradation in Breast Cancer.
Wymant JM; Sayers EJ; Muir D; Jones AT
J Cancer; 2020; 11(11):3288-3302. PubMed ID: 32231734
[TBL] [Abstract][Full Text] [Related]
34. Formation of multimeric antibodies for self-delivery of active monomers.
Dekel Y; Machluf Y; Gefen T; Eidelshtein G; Kotlyar A; Bram Y; Shahar E; Reslane F; Aizenshtein E; Pitcovski J
Drug Deliv; 2017 Nov; 24(1):199-208. PubMed ID: 28156181
[TBL] [Abstract][Full Text] [Related]
35. Bioinformatics and in vitro study reveals ERα as the potential target gene of Honokiol to enhance trastuzumab sensitivity in HER2+ trastuzumab-resistant breast cancer cells.
Putra IMR; Lestari IA; Fatimah N; Hanif N; Ujiantari NSO; Putri DDP; Hermawan A
Comput Biol Chem; 2024 May; 111():108084. PubMed ID: 38805864
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab in the management of early and advanced stage breast cancer.
Bartsch R; Wenzel C; Steger GG
Biologics; 2007 Mar; 1(1):19-31. PubMed ID: 19707345
[TBL] [Abstract][Full Text] [Related]
37. Development of a Nanostructured Platform for Identifying HER2-Heterogeneity of Breast Cancer Cells by Surface-Enhanced Raman Scattering.
Téllez-Plancarte A; Haro-Poniatowski E; Picquart M; Morales-Méndez JG; Lara-Cruz C; Jiménez-Salazar JE; Damián-Matsumura P; Escobar-Alarcón L; Batina N
Nanomaterials (Basel); 2018 Jul; 8(7):. PubMed ID: 30036967
[TBL] [Abstract][Full Text] [Related]
38. The SKBR3 cell-membrane proteome reveals telltales of aberrant cancer cell proliferation and targets for precision medicine applications.
Karcini A; Lazar IM
Sci Rep; 2022 Jun; 12(1):10847. PubMed ID: 35760832
[TBL] [Abstract][Full Text] [Related]
39. Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine.
Fredebohm J; Wolf J; Hoheisel JD; Boettcher M
J Cell Sci; 2013 Aug; 126(Pt 15):3380-9. PubMed ID: 23687379
[TBL] [Abstract][Full Text] [Related]
40. Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY; Miteva MA
J Mol Biol; 2013 Nov; 425(21):3978-92. PubMed ID: 23856621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
